🔎 Trials Near Me

Home › Mga Autoimmune na Sakit › Massachusetts › Boston

Pag-aaral pangklinika para sa Mga Autoimmune na Sakit sa Boston, MA

Isang pag-aaral para sa Mga Autoimmune na Sakit ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Boston. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

Nagre-recruitPhase 3
  • Tufts Medical Center, Boston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07621809

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Nagre-recruitPhase 1
  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT03816345

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Nagre-recruitPhase 3
  • Massachusetts General Hospital, Boston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06722235

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Nagre-recruitPhase 2/3
  • Boston Children's Hospital - Accepting Young Adults and Juvenile Patients, Boston
Edad 6 hanggang 75 · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06154252

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Nagre-recruitPhase 3
  • Massachusetts General Hospital, Boston
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06948318

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Nagre-recruitPhase 1/2
  • Tufts Medical Center, Boston
  • Massachusetts General Hospital, Boston
  • Boston Children's Hospital, Boston
  • at 1 pa
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Ago 26, 2026 · NCT06121297

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

Nagre-recruitPhase 1/2
  • Beth Israel Deaconess Medical Center, Boston
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Ago 13, 2026 · NCT06359041

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Nagre-recruitPhase 3
  • Boston Children's Cancer Center, Boston
Edad 12 pataas · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06056297

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

Nagre-recruitPhase 1
  • Brigham And Womens Hospital, Boston
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 14, 2026 · NCT07115745

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Nagre-recruitObservasyonal na pag-aaral
  • Tufts Medical Center, Boston
  • Beth Israel Deaconess, Boston
  • Dana Farber Cancer Institute, Boston
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545

Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis

Nagre-recruitPhase 1
  • Tufts University, Boston
  • Massachusetts General Hospital, Boston
  • Brigham and Women's Hospital, Boston
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Hun 30, 2026 · NCT06201416

Testimonials and Navigation in Rheumatology

Nagre-recruit
  • Brigham Women's Hospital, Boston
Edad 18 pataas · Lahat ng kasarian · Na-update May 6, 2026 · NCT06469788

Pag-aaral para sa Mga Autoimmune na Sakit sa ibang lungsod

Iba pang pag-aaral sa Boston

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.